{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,11]],"date-time":"2024-06-11T20:36:46Z","timestamp":1718138206606},"reference-count":116,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2003,11,18]],"date-time":"2003-11-18T00:00:00Z","timestamp":1069113600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Fundamemntal Clinical Pharma"],"published-print":{"date-parts":[[2003,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Alzheimer's disease (AD) is a chronic neurodegenerative disorder characterized by a progressive loss of cognitive and functional abilities, associated with various degrees of behavioural disturbances, with a devastating impact on public health and on the whole society. Slowing of cognitive impairment, duration of disease, self\u2010sufficiency and behavioural disturbances represent the best outcomes of the pharmacologic therapy. Cholinesterase inhibitors (ChE\u2010I) have been shown to be effective in the treatment of the cognitive, behavioural, and functional deficits of AD. In addition to ChE\u2010I, a number of studies have been carried out to investigate the possible use of other compounds and pharmacologic strategies; more compounds, postsynaptic muscarinic and nicotinic receptor agonists, are under investigation. The standard suggested care for pharmacologic management of the cognitive and functional disabilities of AD at present consists of treatment with ChE\u2010I. Practice recommendations and treatment guidelines are derived from clinical trials.<\/jats:p>","DOI":"10.1046\/j.1472-8206.2003.00204.x","type":"journal-article","created":{"date-parts":[[2003,11,20]],"date-time":"2003-11-20T21:49:33Z","timestamp":1069364973000},"page":"659-672","update-policy":"http:\/\/dx.doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Clinical pharmacology of anti\u2010Alzheimer drugs"],"prefix":"10.1111","volume":"17","author":[{"given":"Carla","family":"Pettenati","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberta","family":"Annicchiarico","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlo","family":"Caltagirone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2003,11,18]]},"reference":[{"key":"e_1_2_21_2_2","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1212\/WNL.34.7.939","article-title":"Clinical diagnosis of Alzheimer's disease: report of the NINCDS ADRDA Work group, Department of Health and Human services Task force on Alzheimer's disease","volume":"34","author":"Mc Khann G.","year":"1984","journal-title":"Neurology"},{"key":"e_1_2_21_3_2","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.141.11.1356"},{"key":"e_1_2_21_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/0022-3956(75)90026-6"},{"key":"e_1_2_21_5_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002093-199700112-00004"},{"key":"e_1_2_21_6_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.56.6.735-a"},{"key":"e_1_2_21_7_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.56.6.738"},{"key":"e_1_2_21_8_2","first-page":"322","article-title":"The National Institute of Clinical Excellence (NICE) approves drugs for Alzheimer's disease","volume":"190","author":"The National Institute of Clinical Excellence (NICE).","year":"2001","journal-title":"Br. Med. J."},{"key":"e_1_2_21_9_2","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.154.4.1"},{"key":"e_1_2_21_10_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.56.9.1154"},{"key":"e_1_2_21_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(76)91936-X"},{"key":"e_1_2_21_12_2","doi-asserted-by":"publisher","DOI":"10.1159\/000047952"},{"key":"e_1_2_21_13_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.7046051"},{"key":"e_1_2_21_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/0959-4388(95)80022-0"},{"key":"e_1_2_21_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0301-0082(97)00028-2"},{"key":"e_1_2_21_16_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.7058341"},{"key":"e_1_2_21_17_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198604103141506"},{"key":"e_1_2_21_18_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.323.7305.123"},{"key":"e_1_2_21_19_2","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.157.1.4"},{"key":"e_1_2_21_20_2","first-page":"687","article-title":"Neuropsychiatric aspects of Alzheimer's disease: the cholinergic hypothesis revisited","volume":"53","author":"Cummings J.L.","year":"1996","journal-title":"Neurology"},{"key":"e_1_2_21_21_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.55.10.1460"},{"key":"e_1_2_21_22_2","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-199912040-00005"},{"key":"e_1_2_21_23_2","first-page":"181","volume-title":"Cholinesterase inhibitors: from the calabar bean to Alzheimer therapy","author":"E. Giacobini","year":"2000"},{"key":"e_1_2_21_24_2","doi-asserted-by":"crossref","unstructured":"CleggA. BryantJ. NicholsonT.et\u00a0al.Clinical and cost effectiveness of donepezil rivastigmine and galantamine for Alzheimer's disease.NICE ReportAmerican Academy of Neurology (AAN) Philadelphia PA USA 2001.","DOI":"10.3310\/hta5010"},{"key":"e_1_2_21_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(02)80004-2"},{"key":"e_1_2_21_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-977X(97)00079-5"},{"key":"e_1_2_21_27_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.57.3.481"},{"key":"e_1_2_21_28_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.57.4.613"},{"key":"e_1_2_21_29_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.56.11.1388"},{"key":"e_1_2_21_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)03399-7"},{"key":"e_1_2_21_31_2","doi-asserted-by":"publisher","DOI":"10.1155\/1999\/168023"},{"key":"e_1_2_21_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-3223(98)00320-5"},{"key":"e_1_2_21_33_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02816110"},{"key":"e_1_2_21_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0531-5565(00)00077-2"},{"key":"e_1_2_21_35_2","doi-asserted-by":"publisher","DOI":"10.1002\/1531-8249(200012)48:6<913::AID-ANA12>3.0.CO;2-S"},{"key":"e_1_2_21_36_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.55.9.1195"},{"key":"e_1_2_21_37_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.58.3.442"},{"key":"e_1_2_21_38_2","doi-asserted-by":"publisher","DOI":"10.1159\/000017126"},{"key":"e_1_2_21_39_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.158.9.1021"},{"key":"e_1_2_21_40_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.50.1.136"},{"key":"e_1_2_21_41_2","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-199916010-00009"},{"key":"e_1_2_21_42_2","first-page":"66","article-title":"Case report: donepezil in the treatment of advanced Alzheimer'disease","volume":"7","author":"Shua\u2010Haim J.R.","year":"1999","journal-title":"Ann. Long-term Care"},{"key":"e_1_2_21_43_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.57.1.94"},{"key":"e_1_2_21_44_2","first-page":"1","article-title":"Donepezil for mild and moderate Alzheimer's disease","volume":"4","author":"Birks J.S.","year":"1999","journal-title":"The Cochrane Database of Systematic Reviews"},{"key":"e_1_2_21_45_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.57.3.489"},{"key":"e_1_2_21_46_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0278-5846(01)00283-4"},{"key":"e_1_2_21_47_2","first-page":"795","article-title":"Self\u2010rated version. Incorporated in the Philadelphia Geriatric Center. Multilevel Assessment Instrument (MAI)","volume":"24","author":"Physical Self\u2010Maintenance Scale (PSMS)","year":"1988","journal-title":"Psychopharmacol. Bull."},{"key":"e_1_2_21_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(98)80127-6"},{"key":"e_1_2_21_49_2","first-page":"55","article-title":"A randomized trial evaluating the efficacy and safety of ENA 713 rivastigmine tartrate, a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease","volume":"1","author":"Corey\u2010Bloom J.","year":"1998","journal-title":"Int. J. Geriatr. Psychopharmacol."},{"key":"e_1_2_21_50_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.318.7184.633"},{"key":"e_1_2_21_51_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-1331.1999.640423.x"},{"key":"e_1_2_21_52_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.58.3.417"},{"key":"e_1_2_21_53_2","volume-title":"The Cochrane Library","author":"Birks J.","year":"2002"},{"key":"e_1_2_21_54_2","first-page":"46","article-title":"Galanthamine hydrobromide in a long\u2010term treatment of Alzheimer's disease","volume":"1","author":"Thomsen T.","year":"1990","journal-title":"Dementia"},{"key":"e_1_2_21_55_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00316106"},{"key":"e_1_2_21_56_2","first-page":"781","article-title":"Galanthamine and the treatmente of Alzheimer's disease","volume":"8","author":"Wilcock G.K.","year":"1993","journal-title":"Int. J. Geriat. Psychiatry"},{"key":"e_1_2_21_57_2","first-page":"140","volume-title":"Pharmacokinetics and metabolism of galanthamine","author":"Kewitz H."},{"key":"e_1_2_21_58_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.54.12.2261"},{"key":"e_1_2_21_59_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.321.7274.1445"},{"key":"e_1_2_21_60_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.54.12.2269"},{"key":"e_1_2_21_61_2","doi-asserted-by":"publisher","DOI":"10.1002\/gps.409"},{"key":"e_1_2_21_62_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.71.5.589"},{"key":"e_1_2_21_63_2","volume-title":"The Cochrane Library","author":"Olin J.","year":"2002"},{"key":"e_1_2_21_64_2","volume-title":"Invecchiamento cerebrale decline cognitivo demenza un continuum?","author":"Mecocci P.","year":"2002"},{"key":"e_1_2_21_65_2","doi-asserted-by":"publisher","DOI":"10.1096\/fasebj.6.15.1464368"},{"key":"e_1_2_21_66_2","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1523\/JNEUROSCI.12-02-00376.1992","article-title":"Beta\u2010amyloid peptides destabilize calcium homeostasis and render human cortical neurons vulnerable to exitotoxicity","volume":"12","author":"Mattson M.P.","year":"1992","journal-title":"J. Neurosci."},{"key":"e_1_2_21_67_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-8993(95)00669-H"},{"key":"e_1_2_21_68_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02815108"},{"key":"e_1_2_21_69_2","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.180.2.135"},{"key":"e_1_2_21_70_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1099-1166(199902)14:2<135::AID-GPS906>3.0.CO;2-0"},{"key":"e_1_2_21_71_2","volume-title":"The Cochrane Library","author":"Sheriff F.","year":"2002"},{"key":"e_1_2_21_72_2","doi-asserted-by":"crossref","unstructured":"ReisbergB. WindscheifU. FerrisS.H.et\u00a0al.Memantine in moderately severe Alzheimer's disease (AD): results of a placebo\u2010controlled 6\u2010month trial. Conference proceedings World Alzheimer Congress; 9\u201313 July 2000; Washington.","DOI":"10.1016\/S0197-4580(00)83188-7"},{"key":"e_1_2_21_73_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1991.tb00226.x"},{"key":"e_1_2_21_74_2","volume-title":"The Cochrane Library","author":"Laake K.","year":"2002"},{"key":"e_1_2_21_75_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-7091-7508-8_15"},{"key":"e_1_2_21_76_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.48.3.626"},{"key":"e_1_2_21_77_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.47.2.425"},{"key":"e_1_2_21_78_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.58.7.1050"},{"key":"e_1_2_21_79_2","volume-title":"The Cochrane Library","author":"Tabet N.","year":"2002"},{"key":"e_1_2_21_80_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199704243361704"},{"key":"e_1_2_21_81_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002093-199809000-00001"},{"key":"e_1_2_21_82_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.1997.tb01476.x"},{"key":"e_1_2_21_83_2","volume-title":"The Cochrane Library","author":"Tabet N.","year":"2002"},{"key":"e_1_2_21_84_2","volume-title":"The Cochrane Library","author":"Birks J.","year":"2002"},{"key":"e_1_2_21_85_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(00)00547-7"},{"key":"e_1_2_21_86_2","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-200014040-00003"},{"key":"e_1_2_21_87_2","volume-title":"The Cochrane Library","author":"Fioravanti M.","year":"2002"},{"key":"e_1_2_21_88_2","volume-title":"The Cochrane Library","author":"Flicker L.","year":"2002"},{"key":"e_1_2_21_89_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.48.1.132"},{"key":"e_1_2_21_90_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.49.6.1498"},{"key":"e_1_2_21_91_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.48.6.1517"},{"key":"e_1_2_21_92_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.58.3.435"},{"key":"e_1_2_21_93_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200104193441604"},{"key":"e_1_2_21_94_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.1994.tb06580.x"},{"key":"e_1_2_21_95_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.48.5_Suppl_7.36S"},{"key":"e_1_2_21_96_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.283.8.1007"},{"key":"e_1_2_21_97_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0306-4522(00)00410-3"},{"key":"e_1_2_21_98_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.279.9.688"},{"key":"e_1_2_21_99_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-115-6-455"},{"key":"e_1_2_21_100_2","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.aje.a008678"},{"key":"e_1_2_21_101_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.285.11.1489"},{"key":"e_1_2_21_102_2","volume-title":"The Cochrane Library","author":"Hogervost E.","year":"2002"},{"key":"e_1_2_21_103_2","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s007020200044","article-title":"Alzheimer's vaccine: a cure as dangerous as the disease?","volume":"109","author":"Munch G.","year":"2002","journal-title":"J. Neural. Transm."},{"key":"e_1_2_21_104_2","doi-asserted-by":"publisher","DOI":"10.1038\/415462a"},{"key":"e_1_2_21_105_2","article-title":"Alzheimer's vaccine permanently shelved","volume":"2","author":"Weiss R.","year":"2002","journal-title":"Washington Post"},{"key":"e_1_2_21_106_2","doi-asserted-by":"publisher","DOI":"10.1038\/78682"},{"key":"e_1_2_21_107_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0166-2236(99)01541-6"},{"key":"e_1_2_21_108_2","doi-asserted-by":"publisher","DOI":"10.1089\/10445490152717604"},{"key":"e_1_2_21_109_2","doi-asserted-by":"publisher","DOI":"10.1038\/22124"},{"key":"e_1_2_21_110_2","article-title":"New class of inhibitors of amyloid\u2010beta (Abeta) fibril formation: Implications for the mechanism of pathogenesis in Alzheimer's disease","volume":"6","author":"Lashuel H.A.","year":"2002","journal-title":"J. Biol. Chem."},{"key":"e_1_2_21_111_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0197-0186(02)00050-5"},{"key":"e_1_2_21_112_2","doi-asserted-by":"publisher","DOI":"10.1038\/417254a"},{"key":"e_1_2_21_113_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.122249699"},{"key":"e_1_2_21_114_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0896-6273(01)00317-8"},{"key":"e_1_2_21_115_2","first-page":"1","article-title":"Practice guidelines for the treatment of patients with Alzheimer disease and other dementias of late life","volume":"154","author":"American Psychiatric Association Work group on Alzheimer disease and related dementias","year":"1997","journal-title":"Am. J. Psychiatry"},{"key":"e_1_2_21_116_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0025-7125(02)00007-X"},{"key":"e_1_2_21_117_2","doi-asserted-by":"publisher","DOI":"10.1097\/00019442-200303000-00004"}],"container-title":["Fundamental &amp; Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1472-8206.2003.00204.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1472-8206.2003.00204.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T05:48:13Z","timestamp":1697176093000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1472-8206.2003.00204.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,11,18]]},"references-count":116,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2003,12]]}},"alternative-id":["10.1046\/j.1472-8206.2003.00204.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1472-8206.2003.00204.x","archive":["Portico"],"relation":{},"ISSN":["0767-3981","1472-8206"],"issn-type":[{"value":"0767-3981","type":"print"},{"value":"1472-8206","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,11,18]]},"assertion":[{"value":"2003-11-18","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}